(E)-6-methoxy-hex-2-enoic acid ethyl ester | 1100718-82-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-6-methoxy-hex-2-enoic acid ethyl ester
• 英文别名: (E)-ethyl-6-methoxyhex-2-enoate；ethyl (E)-6-methoxyhex-2-enoate
• CAS: 1100718-82-8
• 化学式: C₉H₁₆O₃
• 分子量: 172.224
• InChiKey: TWJDUQNHSCWAFU-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-6-methoxy-hex-2-enoic acid ethyl ester 在 盐酸 、 三氟甲磺酸酐 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 34.5h， 生成 6-(3-methoxypropyl)-5,6-dihydrothieno[2,3-b]thiopyran-4-one
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of NO-Donor Containing Carbonic Anhydrase Inhibitors To Lower Intraocular Pressure

  摘要：

  The antiglaucoma drugs dorzolamide (1) and brinzolamide (2) lower intraocular pressure (TOP) by inhibiting the carbonic anhydrase (CA) enzyme to reduce aqueous humor production. The introduction of a nitric oxide (NO) donor into the alkyl side chain of dorzolamide (1) and brinzolamide (2) has led to the discovery of NO-dorzolamide 3a and NO-brinzolamide 4a, which could lower TOP through two mechanisms: CA inhibition to decrease aqueous humor secretion (reduce inflow) and NO release to increase aqueous humor drainage (increase outflow). Compounds 3a and 4a have shown improved efficacy of lowering IOP in both rabbits and monkeys compared to brinzolamide (2).

  DOI：

  10.1021/acs.jmedchem.5b00043
• 作为产物：
  描述：

  4-甲氧基-1-丁醇 在 sodium hydride 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.25h， 生成 (E)-6-methoxy-hex-2-enoic acid ethyl ester
  参考文献：
  名称：

  [EN] NRF2 REGULATORS
  [FR] RÉGULATEURS DE NRF2

  摘要：

  这项发明涉及双芳基类似物，含有它们的药物组合物以及它们作为Nrf2调节剂的用途。

  公开号：

  WO2015092713A1

文献信息

• [EN] NRF2 REGULATORS<br/>[FR] RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015092713A1

  公开（公告）日：2015-06-25

  The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.

  这项发明涉及双芳基类似物，含有它们的药物组合物以及它们作为Nrf2调节剂的用途。
• [EN] INHIBITORS OF CARBONIC ANHYDRASE<br/>[FR] INHIBITEURS D'ANHYDRASE CARBONIQUE
  申请人：PFIZER

  公开号：WO2009007814A1

  公开（公告）日：2009-01-15

  The invention relates to a compound of formula (I) and to pharmaceutically acceptable salts and solvates thereof. The invention also relates to methods of treating glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy, retinal vasculopathies and intraocular pressure in mammals by administering the compound, and to pharmaceutical compositions which contain the compound for such treatments. The invention also relates to methods of preparing the compound.

  本发明涉及一种公式(I)的化合物，以及其药学上可接受的盐和溶剂化物。本发明还涉及通过给予该化合物治疗青光眼、眼压增高、老年性黄斑变性、糖尿病性黄斑水肿、糖尿病视网膜病变、高血压性视网膜病变、视网膜血管病变和哺乳动物眼内压力的方法，以及包含该化合物用于这些治疗的制药组合物。本发明还涉及制备该化合物的方法。
• NRF2 REGULATORS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20160318917A1

  公开（公告）日：2016-11-03

  The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
• NRF2 Regulators
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20190002454A1

  公开（公告）日：2019-01-03

  The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
• Design, Synthesis, and Evaluation of NO-Donor Containing Carbonic Anhydrase Inhibitors To Lower Intraocular Pressure
  作者：Qinhua Huang、Eugene Y. Rui、Morena Cobbs、Dac M. Dinh、Hovhannes J. Gukasyan、Jennifer A. Lafontaine、Saurabh Mehta、Brian D. Patterson、David A. Rewolinski、Paul F. Richardson、Martin P. Edwards

  DOI：10.1021/acs.jmedchem.5b00043

  日期：2015.3.26

  The antiglaucoma drugs dorzolamide (1) and brinzolamide (2) lower intraocular pressure (TOP) by inhibiting the carbonic anhydrase (CA) enzyme to reduce aqueous humor production. The introduction of a nitric oxide (NO) donor into the alkyl side chain of dorzolamide (1) and brinzolamide (2) has led to the discovery of NO-dorzolamide 3a and NO-brinzolamide 4a, which could lower TOP through two mechanisms: CA inhibition to decrease aqueous humor secretion (reduce inflow) and NO release to increase aqueous humor drainage (increase outflow). Compounds 3a and 4a have shown improved efficacy of lowering IOP in both rabbits and monkeys compared to brinzolamide (2).